Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.4823
-0.0160 (-3.21%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Stock Forecast
LCTX's stock price has decreased by -56.15% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Lineage Cell Therapeutics stock have an average target of 4.20, with a low estimate of 2.00 and a high estimate of 9.00. The average target predicts an increase of 770.83% from the current stock price of 0.48.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 14, 2025.
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 5 | 5 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +522.02% | Mar 14, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +314.68% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +1,766.06% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +1,766.06% | Feb 11, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 → $2 | Strong Buy | Maintains | $3 → $2 | +314.68% | Feb 11, 2025 |
Financial Forecast
Revenue This Year
8.26M
from 9.50M
Decreased by -13.02%
Revenue Next Year
27.48M
from 8.26M
Increased by 232.66%
EPS This Year
-0.09
from -0.09
EPS Next Year
-0.05
from -0.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.5M | 47.3M | 194.0M | ||
| Avg | 8.3M | 27.5M | 53.3M | ||
| Low | 2.9M | n/a | 4.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.6% | 471.9% | 605.7% | ||
| Avg | -13.0% | 232.7% | 94.0% | ||
| Low | -69.0% | - | -85.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.01 | 0.03 | -0.05 | ||
| Avg | -0.09 | -0.05 | -0.09 | ||
| Low | -0.15 | -0.15 | -0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.